comparemela.com
Home
Live Updates
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1 : comparemela.com
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development
In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated...
Related Keywords
France ,
United States ,
Japan ,
Sarah Sheikh ,
Yves Dauvilliers ,
Wake Disorders Center ,
Exchange Commission ,
Takeda Pharmaceutical Company Limited ,
Department Of Neurology ,
New England Journal ,
Orexin Receptor ,
Narcolepsy Type ,
Sleep Wake Disorders Center ,
Gui De Chauliac Hospital ,
Wakefulness Test ,
Epworth Sleepiness Scale ,
Efficacy Results ,
Neuroscience Therapeutic Area Unit ,
Annual Report ,
comparemela.com © 2020. All Rights Reserved.